SCHEMBL4746394

SCHEMBL4746394

Cc1ccc2c(c1)c(-c1cccc3c(-c4cc5c6ccc(C)c7c6c(cc5c5ccc(C)cc45)-c4ncccc4-7)cccc13)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
MAPT P10636 3/20 0.32
HTT P42858 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
MAPK1 P28482 1/20 0.32
AGTR1 P30556 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CCR1 P32246 1/20 0.32
CCR8 P51685 1/20 0.32
USP2 O75604 1/20 0.31
RECQL P46063 1/20 0.31
RAB9A P51151 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31
CCNB2 O95067 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746409 0.96 PDK2 (0.33) MEN1KMT2AMAPTHTTTDP1
SCHEMBL4745860 0.94 MAOA (0.35) MAPTKDM4ECCR1CCR8CYP1A2
SCHEMBL4746054 0.94 CA12 (0.37) TOP2AALDH1A1
SCHEMBL4746272 0.94 MAPT (0.32) MEN1KMT2AMAPTHTTTDP1
SCHEMBL4745880 0.93 MAPT (0.34) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL4745982 0.93 ALDH1A1 (0.34) MEN1KMT2AMAPTHTTTDP1
SCHEMBL4746466 0.93 TOP2A (0.32) MEN1KMT2AMAPTHTTTDP1
SCHEMBL4745985 0.92 BCHE (0.33) PDK2TOP2ABCHEALDH1A1
SCHEMBL4746461 0.92 TOP2A (0.33) MEN1KMT2AMAPTHTTTDP1
SCHEMBL4745959 0.92 CYP1A2 (0.35) MEN1KMT2AMAPTHTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 MEN1 2573/4885KMT2A 781/4885MAPT 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.